Date of Award
Open Access Thesis
Master of Medical Science (MMSc)
Jeffrey Turner, MD
Chronic kidney disease is a serious illness that reduces the life span and quality of life in diagnosed patients. Despite advancements in medical management, progression to end-stage renal disease persists. While the renoprotective effects of sodium-glucose cotransporter-2 inhibitors in diabetes mellitus patients are well-documented, no studies have examined the efficacy of these drugs in treating renal disease in the absence of diabetes mellitus. The objective of this trial is to determine whether canagliflozin, a sodium-glucose cotransporter-2 inhibitor, can improve renal outcomes in patients with non-diabetic chronic kidney disease. Utilizing a double-blind, randomized control trial design, we will examine the effects of canagliflozin on patients’ glomerular filtration rate and progression to end-stage renal disease. We hypothesize that adding canagliflozin to the standard of care, including a maximum tolerated labeled dose of an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker, will decrease the mean glomerular filtration rate decline per year.
Wigley, Mia Bronte, "Canagliflozin To Slow Renal Insufficiency Progression in Non-Diabetic Chronic Kidney Disease" (2020). Yale School of Medicine Physician Associate Program Theses. 35.
This Article is Open Access